X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (110384) 110384
Newsletter (14410) 14410
Publication (9729) 9729
Newspaper Article (3476) 3476
Patent (1144) 1144
Book Chapter (949) 949
Book Review (936) 936
Magazine Article (423) 423
Dissertation (277) 277
Book / eBook (184) 184
Conference Proceeding (174) 174
Trade Publication Article (76) 76
Web Resource (51) 51
Reference (44) 44
Transcript (44) 44
Data Set (25) 25
Paper (15) 15
Government Document (6) 6
Streaming Video (4) 4
Journal / eJournal (3) 3
Presentation (2) 2
Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (46499) 46499
humans (42502) 42502
index medicus (40167) 40167
male (37975) 37975
fatty acids (28699) 28699
fatty liver (26623) 26623
female (25659) 25659
liver (23954) 23954
rats (21614) 21614
liver - metabolism (18587) 18587
research (18486) 18486
mice (15880) 15880
metabolism (15127) 15127
obesity (14301) 14301
biochemistry & molecular biology (13548) 13548
adult (12634) 12634
lipids (12572) 12572
middle aged (12151) 12151
insulin resistance (11955) 11955
physiological aspects (11617) 11617
diet (11440) 11440
insulin-resistance (10175) 10175
liver diseases (9764) 9764
gastroenterology & hepatology (9723) 9723
lipid metabolism (9245) 9245
nutrition & dietetics (9178) 9178
fatty acids - metabolism (9078) 9078
endocrinology & metabolism (8755) 8755
risk factors (8718) 8718
analysis (8595) 8595
metabolic syndrome (8059) 8059
medical research (7859) 7859
gene expression (7675) 7675
inflammation (7651) 7651
liver - pathology (7613) 7613
rodents (7596) 7596
liver - drug effects (7508) 7508
cholesterol (7473) 7473
oxidative stress (7313) 7313
diabetes (7113) 7113
glucose (7102) 7102
insulin (7017) 7017
fatty liver-disease (7009) 7009
medicine, experimental (6993) 6993
proteins (6951) 6951
non-alcoholic fatty liver disease (6911) 6911
health aspects (6823) 6823
aged (6120) 6120
steatosis (6015) 6015
reports (5978) 5978
physiology (5907) 5907
disease (5834) 5834
expression (5827) 5827
fatty liver - pathology (5766) 5766
research article (5667) 5667
medicine (5647) 5647
enzymes (5641) 5641
mice, inbred c57bl (5411) 5411
article (5306) 5306
cell biology (5300) 5300
triglycerides (5286) 5286
fatty-acids (5142) 5142
fibrosis (5129) 5129
nonalcoholic steatohepatitis (5005) 5005
hepatic steatosis (4972) 4972
pharmacology & pharmacy (4972) 4972
multidisciplinary sciences (4903) 4903
fatty liver - metabolism (4828) 4828
nutrition (4735) 4735
liver - enzymology (4646) 4646
gene-expression (4615) 4615
type 2 diabetes (4571) 4571
care and treatment (4515) 4515
steatohepatitis (4336) 4336
triglycerides - blood (4288) 4288
body weight (4269) 4269
adipose-tissue (4253) 4253
fatty acids, nonesterified - blood (4144) 4144
fatty liver - etiology (4077) 4077
triglycerides - metabolism (4019) 4019
rats, wistar (4010) 4010
disease models, animal (3936) 3936
science (3905) 3905
prevalence (3901) 3901
rats, sprague-dawley (3896) 3896
oxidation-reduction (3893) 3893
medicine, research & experimental (3810) 3810
unsaturated fatty acids (3756) 3756
studies (3745) 3745
nonalcoholic fatty liver disease (3691) 3691
time factors (3632) 3632
body mass index (3598) 3598
pregnancy (3584) 3584
liver cirrhosis (3504) 3504
biochemistry (3494) 3494
cancer (3490) 3490
genetic aspects (3473) 3473
blood glucose - metabolism (3455) 3455
dietary supplements (3376) 3376
apoptosis (3368) 3368
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (73) 73
Online Resources - Online (14) 14
UofT at Mississauga - Stacks (12) 12
Chemistry (A D Allen) - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Engineering & Comp. Sci. - Stacks (5) 5
UofT at Scarborough - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Gerstein Science - Theses (1) 1
Royal Ontario Museum - May be requested (1) 1
Scarborough Hospital - Online (1) 1
University Archives - Archives (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (122104) 122104
German (1788) 1788
French (1039) 1039
Chinese (1000) 1000
Japanese (987) 987
Russian (949) 949
Danish (671) 671
Spanish (644) 644
Italian (510) 510
Korean (509) 509
Polish (218) 218
Portuguese (176) 176
Swedish (162) 162
Hungarian (103) 103
Czech (98) 98
Ukrainian (60) 60
Dutch (57) 57
Turkish (55) 55
Romanian (51) 51
Persian (48) 48
Slovak (43) 43
Bulgarian (33) 33
Norwegian (19) 19
Croatian (18) 18
Serbian (13) 13
Icelandic (10) 10
Finnish (9) 9
Bosnian (4) 4
Hebrew (4) 4
Lithuanian (4) 4
Indonesian (3) 3
Slovenian (3) 3
Catalan (2) 2
Arabic (1) 1
Estonian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


World Journal of Gastroenterology, ISSN 1007-9327, 11/2013, Volume 19, Issue 41, pp. 6969 - 6978
The 148 Isoleucine to Methionine protein variant (I148M) of patatin-like phospholipase domain-containing 3 (PNPLA3), a protein is expressed in the liver and is... 
Liver disease | Patatin-like phospholipase domain-containing 3 | Chronic hepatitis C virus hepatitis | Genetics | Hepatocellular carcinoma | Nonalcoholic fatty liver disease | Single nucleotide polymorphism | Fibrogenesis | Alcoholic liver disease | Steatosis | CHRONIC HEPATITIS-C | NONALCOHOLIC STEATOHEPATITIS | GREATER-THAN-G | B-VIRUS INFECTION | HEPATOCELLULAR-CARCINOMA | INSULIN-RESISTANCE | FATTY LIVER | DOMAIN-CONTAINING 3 | GENETIC VARIANT | GASTROENTEROLOGY & HEPATOLOGY | GENOME-WIDE ASSOCIATION | Cholangitis, Sclerosing - enzymology | Hepatitis C, Chronic - pathology | Fatty Liver - pathology | Humans | Cholangitis, Sclerosing - genetics | Fatty Liver - complications | Hepatitis B, Chronic - enzymology | Hepatitis C, Chronic - complications | Liver Cirrhosis - enzymology | Hemochromatosis - pathology | Fatty Liver, Alcoholic - genetics | Hepatitis B, Chronic - genetics | Liver Cirrhosis, Alcoholic - enzymology | Hepatitis C, Chronic - enzymology | Fatty Liver - enzymology | Non-alcoholic Fatty Liver Disease | Liver Neoplasms - pathology | Fatty Liver, Alcoholic - pathology | Liver Neoplasms - enzymology | Fatty Liver, Alcoholic - enzymology | Hepatitis B, Chronic - pathology | Liver Cirrhosis - genetics | Hemochromatosis - genetics | Fatty Liver - genetics | Genetic Predisposition to Disease | Liver Neoplasms - genetics | Liver Cirrhosis, Alcoholic - pathology | Membrane Proteins - genetics | Risk Factors | Hemochromatosis - enzymology | Disease Progression | Polymorphism, Genetic | Cholangitis, Sclerosing - pathology | Fatty Liver, Alcoholic - complications | Liver Cirrhosis, Alcoholic - genetics | Phenotype | Liver Cirrhosis - pathology | Carcinoma, Hepatocellular | Hepatitis C, Chronic - genetics | Lipase - genetics | Review | Gastroenterologi | Hepatocellular | Gastroenterology and Hepatology
Journal Article
Hepatology, ISSN 0270-9139, 04/2017, Volume 65, Issue 4, pp. 1165 - 1180
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 2, pp. 307 - 320
c-Jun-N-terminal kinase (JNK) is a mitogen-activated protein kinase family member that is activated by diverse stimuli, including cytokines (such as tumor... 
Gastroenterology and Hepatology | c-Jun | MAPK | Acetaminophen | TNF | Insulin Resistance | Hepatocellular Carcinoma | N-TERMINAL KINASE | JUN NH2-TERMINAL KINASE | ENDOPLASMIC-RETICULUM STRESS | TNF-INDUCED APOPTOSIS | KAPPA-B | MITOCHONDRIAL PERMEABILITY TRANSITION | HEPATOCYTE SURVIVAL | INSULIN-RESISTANCE | COMPENSATORY PROLIFERATION | GASTROENTEROLOGY & HEPATOLOGY | Acetaminophen - adverse effects | Liver Transplantation | Humans | JNK Mitogen-Activated Protein Kinases - metabolism | Metabolic Syndrome - metabolism | Liver - physiopathology | Metabolic Syndrome - drug therapy | MAP Kinase Signaling System | Carcinoma, Hepatocellular - drug therapy | Analgesics, Non-Narcotic - adverse effects | Cell Death | Biomarkers - metabolism | Liver Regeneration | Fatty Liver - metabolism | JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors | Liver - metabolism | Liver Neoplasms - drug therapy | Fatty Liver - drug therapy | Animals | Chemical and Drug Induced Liver Injury - metabolism | Protein Kinase Inhibitors - therapeutic use | Chemical and Drug Induced Liver Injury - drug therapy | JNK Mitogen-Activated Protein Kinases - physiology | Liver Neoplasms - metabolism | Liver - physiology | Liver Diseases - drug therapy | Mice | Primary Graft Dysfunction - metabolism | Liver Diseases - physiopathology | Liver Diseases - metabolism | Carcinoma, Hepatocellular - metabolism | Enzymes | Medical colleges | Platelet-derived growth factor | Liver diseases | Isoenzymes | Genes | Liver | Development and progression | Transforming growth factors | Fatty acids | Liver cancer | Epidermal growth factor | Interleukins | DNA | Genetically modified organisms | Physiological aspects | Insulin resistance | Tumor proteins | Mitogens | Protein kinases | Tumors | Index Medicus | Abridged Index Medicus | acetaminophen | insulin resistance | hepatocellular carcinoma
Journal Article
Drug Metabolism Reviews, ISSN 0360-2532, 2/2012, Volume 44, Issue 1, pp. 34 - 87
A frequent mechanism for drug-induced liver injury (DILI) is the formation of reactive metabolites that trigger hepatitis through direct toxicity or immune... 
drug-induced liver injury | susceptibility | idiosyncrasy | liver | hepatotoxicity | mitochondria | mitochondrial DNA | mitochondrial permeability transition | mitochondrial dysfunction | Adverse drug reactions | hepatitis | steatosis | adverse drug reactions | PERMEABILITY TRANSITION PORE | COA DEHYDROGENASE-DEFICIENCY | ENDOPLASMIC-RETICULUM STRESS | HUMAN-IMMUNODEFICIENCY-VIRUS | ISOLATED RAT HEPATOCYTES | REVERSE-TRANSCRIPTASE INHIBITORS | HEPATITIS-C VIRUS | HEPATOCYTE PLASMA-MEMBRANE | FATTY-ACID OXIDATION | MANGANESE SUPEROXIDE-DISMUTASE | PHARMACOLOGY & PHARMACY | Liver - pathology | Fatty Liver - metabolism | Mitochondria, Liver - pathology | Reactive Oxygen Species - metabolism | Oxidation-Reduction | DNA, Mitochondrial - drug effects | Fatty Liver - pathology | Mitochondria, Liver - metabolism | Humans | Liver - metabolism | Mitochondrial Proteins - biosynthesis | Mitochondria, Liver - drug effects | Mitochondrial Proteins - drug effects | Pharmaceutical Preparations - metabolism | Chemical and Drug Induced Liver Injury - metabolism | Immune System - metabolism | Drug-Related Side Effects and Adverse Reactions | Mitochondria, Liver - ultrastructure | Cell Respiration - drug effects | Chemical and Drug Induced Liver Injury - pathology | DNA, Mitochondrial - biosynthesis | Fatty Liver - etiology | Index Medicus | Hépatology and Gastroenterology | Reactive Oxygen Species | Liver | DNA, Mitochondrial | Drug-Induced Liver Injury | Mitochondrial Proteins | Fatty Liver | Mitochondria, Liver | Life Sciences | Human health and pathology | Cell Respiration | Immune System | Pharmaceutical Preparations
Journal Article
Gut, ISSN 0017-5749, 03/2012, Volume 61, Issue 3, pp. 416 - 426
ObjectiveMonocyte chemoattractant protein-1 (MCP-1, CCL2), the primary ligand for chemokine receptor C–C chemokine receptor 2 (CCR2), is increased in livers of... 
FIBROSIS | STEATOSIS | INSULIN-RESISTANCE | INFLAMMATION | BONE-MARROW | DISEASE | MONOCYTE SUBSETS | MICE | SPIEGELMER | GASTROENTEROLOGY & HEPATOLOGY | CCR2 | Liver - pathology | Carbon Tetrachloride | Liver Cirrhosis, Experimental - etiology | Bone Marrow Cells - physiology | Male | Chemical and Drug Induced Liver Injury, Chronic - drug therapy | Liver Cirrhosis, Experimental - prevention & control | Non-alcoholic Fatty Liver Disease | Chemokine CCL2 - physiology | Bone Marrow Cells - drug effects | Chemical and Drug Induced Liver Injury - pathology | Chemical and Drug Induced Liver Injury, Chronic - complications | Macrophages - physiology | Aptamers, Nucleotide - pharmacology | Drug Evaluation, Preclinical - methods | Acute Disease | Cytokines - metabolism | Liver - metabolism | Mice, Inbred C57BL | Cells, Cultured | Fatty Liver - prevention & control | Aptamers, Nucleotide - therapeutic use | Chemotaxis - drug effects | Chemical and Drug Induced Liver Injury, Chronic - pathology | Disease Progression | Fatty Liver - drug therapy | Animals | Chemical and Drug Induced Liver Injury - complications | Chemical and Drug Induced Liver Injury - drug therapy | Macrophages - drug effects | Mice | Chemokine CCL2 - antagonists & inhibitors | Fatty Liver - etiology | Care and treatment | Liver diseases | Fibrosis | Models | Research | Macrophages | Chemokine receptors | Studies | Cytokines | Polyethylene glycol | Rodents | Liver | Clinical trials | Tumor necrosis factor-TNF | Inflammation | Diabetes | Metabolic disorders | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2016, Volume 22, Issue 32, pp. 7236 - 7251
Non-alcoholic fatty liver disease(NAFLD) is the most common cause of chronic liver disease worldwide. Currently, the routinely used modalities are unable to... 
elastography;Controlled<